ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO479

Early Use and Effectiveness of Finerenone in US Patients with CKD and Type 2 Diabetes: A FOUNTAIN Platform Analysis

Session Information

Category: Diabetic Kidney Disease

  • 702 Diabetic Kidney Disease: Clinical

Authors

  • Oberprieler, Nikolaus G., Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany
  • Kovesdy, Csaba P., University of Tennessee, Memphis, Tennessee, United States
  • Layton, J. Bradley, RTI Health Solutions Research Triangle Park, Research Triangle Park, North Carolina, United States
  • Gay, Alain, Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany
  • Farjat, Alfredo E., Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany
  • Liu, Fangfang, Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany
  • Johannes, Catherine B., RTI Health Solutions Research Triangle Park, Research Triangle Park, North Carolina, United States
  • Pladevall-Vila, Manel, RTI Health Solutions Barcelona, Barcelona, Catalunya, Spain
  • Vizcaya, David, Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany
Background

Based on evidence from clinical trials, finerenone reduces the risk of cardiovascular and renal complications among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Evidence from finerenone use in real-world clinical practice is lacking.

Methods

Longitudinal (from July 2021 to latest data available) cohort study using two existing US electronic health record and insurance claim databases. Among individuals with both CKD and T2D, a single cohort of new users of finerenone is described (patient characteristics, comorbidities, comedications, and incidence rates of cardiovascular and renal outcomes, including eGFR and UACR changes over time).

Results

Preliminarily, results from an initial feasibility assessment show a total of 662 new users of finerenone who had a mean (SD) age of 72.1 (8.3) years with 46.6% being female. The most common comorbidities at baseline were hypertension (98.3%), hyperlipidemia (87.5%), peripheral vascular disease (66.8%), neuropathy (53.7%), retinopathy (35.5%), and congestive heart failure (34.4%); 9.9% of individuals had acute coronary syndrome and 6.5% experienced a stroke prior to finerenone initiation. Baseline comedication use was common with 70.5% of individuals using an angiotensin-converting enzyme inhibitor (ACE) or an angiotensin receptor blocker (ARB), 60.2% a beta-blocker, and 50.6% calcium channel blockers (CCB). Furthermore, 90.9% of finerenone users used anti-hyperglycemic medications, including insulins (46.6%), metformin (42.9%), sodium-glucose cotransporter-2 (SGLT2) inhibitors (42.3%), and glucagon-like peptide-1 (GLP-1) receptor agonists (35.2%). Complete results from the full Optum EHR and OM1 Real-World Data CloudTM databases, including incidence rates of cardiovascular and renal outcomes, will be presented as part of the conference presentation.

Conclusion

Early evidence from patients who receive finerenone as part of clinical practice in the US suggests that finerenone is used independently of demographic and clinical characteristics. Furthermore, this analysis of early adopters suggests that finerenone is used as a complementary treatment option to other renal and cardiovascular protective medication-classes recommended for patients with CKD and T2D.

Funding

  • Commercial Support – Bayer AG